Blue Trust’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
Blue Trust's DNLI Position: Q3 2026 in Review
Blue Trust reduced its Denali Therapeutics (DNLI) stake by 20% in Q3 2026, selling an estimated $187 and leaving 32 shares worth $651. The position accounts for ﹤0.01% of the portfolio, ranked #2251.
Blue Trust first reported a position in DNLI in Q3 2022 and has held it in 12 quarters since. The position peaked at $1.68K in Q2 2024. 223 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.
- Blue Trust held 32 shares of Denali Therapeutics worth $651 as of Q3 2026.
- Blue Trust sold 8 Denali Therapeutics shares in Q3 2026, an estimated $187.
- Denali Therapeutics made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #2251 holding.
- Blue Trust first reported a position in Denali Therapeutics in Q3 2022 and has held it in 12 quarters since.
- Blue Trust's Denali Therapeutics position peaked at $1.68K in Q2 2024.
- 223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.
Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.